Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Platform Provides Consumers and Physicians with Data Needed to Make Informed Health Decisions on COVID-19

  • Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system.
  • The company’s AditxtScore(TM) for COVID-19 generates an AditxtScore(TM), which offers a detailed profile of a person’s immune response for SARS-CoV-2, allowing consumers and their physicians to understand, manage, and monitor their level of immune response to the virus, thus allowing them to make informed health decisions
  • Aditxt’s platform is initially focusing on SARS-CoV-2, the virus that causes COVID-19, in recognition of the importance of immune monitoring and profiling in determining the course of action related to the virus. 

Though the COVID-19 pandemic is now in its third year, as noted in a recent Scientific American article (https://ibn.fm/owGS8), scientists are still unsure whether there is a measure that could tell if people are protected from the virus. Still, different measures, collectively known as “correlates of protection,” define the immune response that a vaccine or viral infection would have to trigger to protect an individual from future infection. Two of these measures, neutralizing antibodies and T cells, are instrumental in immune profiling, a process that seeks to identify a person’s specific immune responses to the virus.  

And as a 2021 journal article discussing immune profiling of COVID-19 writes: “Variability in the host immune response is likely to play a major role in determining the course of SARS-CoV-2 infection. Given this, there is a need to apply immune profiling to better understand the interaction of this virus with the human immune system and how this influences clinical outcomes and informs vaccine development” (https://ibn.fm/g4cnr).

Separately, Dr. Shivani Amdekar, a Medical Director at the Oxford Immune Algorithmics AI company, believes that deep immune monitoring – which involves measuring specialized immune cells – could be instrumental in advancing a test for long COVID. Moreover, the data collected from such initiatives, especially on a large scale, Dr. Shivani notes, could aid in uncovering potentially important relationships that may lead to useful therapeutic solutions for long COVID (https://ibn.fm/eT0FI).

Aditxt (NASDAQ: ADTX), a biotech innovation company, understands this underlying value of immune monitoring and has continually worked to build awareness and visibility among consumers and healthcare providers of its AditxtScore(TM) Immune Monitoring Platform. With its inaugural focus being COVID-19, the platform creates comprehensive profiles of people’s immune systems, allowing them to understand, manage, and monitor their individual reactions to the virus. 

In addition, AditxtScore for COVID-19 provides timely reports on the immune status and vulnerability to the SARS-CoV-2 virus, providing consumers and their physicians with the data needed to make informed health decisions. 

AditxtScore(TM) is a timely technology amid warnings by the Biden administration that the U.S. could see 100 million COVID-19 infections and a potentially substantial wave of deaths this fall and winter. The government attributes this wave to emerging omicron subvariants that can escape the vaccines (https://ibn.fm/7L4Xc). 

“In 2020, when the pandemic started, governments and public health agencies all over the world did everything possible to control infection. Infection status was the focus and, understandably so, to minimize the loss of lives,” Aditxt CEO and Founder Amro Albanna said in 2021 during a press conference in which the company announced it would open the AditxtScore(TM) Immune Monitoring Center in Richmond (https://ibn.fm/0ZaHm). “As we move forward, we must transition from focusing on infection status to protection status. We need to understand our individual immunity status so we can make better decisions as we move forward.”

But Aditxt’s sights are also set on other maladies, as AditxtScore(TM) is being designed for other applications in infectious diseases, autoimmunity, and organ transplantation.  

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

For more information, visit the company’s websites at www.Aditxt.com and www.AditxtScore.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
Editor@TinyGems.net

TinyGems is part of the InvestorBrandNetwork

Archives

Select A Month

Contact us: (310) 299-1717